Drug Trial Radar · NCT05940116
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
322
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Jul 30, 2025
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.
Conditions
- Non-Small Cell Lung Cancer
- Solid Tumor
Interventions
HS-20117Drug
Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined. Phase Ib: patients will receive HS-20117 at MED or MAD
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Phase 1a] Maximum tolerated dose (MTD) of HS-20117Time frame: Cycle 1 (28 days)
- [Phase 1a] Maximum applicable dose (MAD) of HS-20117Time frame: Cycle 1 (28 days)
- [Phase 1b] Efficacy of HS-20117: Objective response rate (ORR)Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.